Here I will attempt to gather and decode euphemisms (saccharine words covering up the dismal reality, e.g., climate change for global warming) and dysphemisms (derogatory terms for neutral ones, e.g., warmist for people who acknowledge the facts of global warming) of corporate-speak.
“Crop Protection Agents” = pesticides
Example: Philip Morris attempting to use the natural anti-pest properties of tobacco to make the claim that tobacco is better for the environment than food crops (remember the neonicotinoid pesticides that are decimating bee and butterfly populations? They come from tobacco)
Although many young academics rightfully complain of being used for their expertise while failing to receive either the remuneration or job security fitting to their contribution, it is always humorous to hear statements that openly admit this unspoken condition.
Upon my usual investigations of the Industry Documents, I came across a RJ Reynolds’s tobacco company document emphasizing the point. Their Biochemical/Biobehavior devision wrote:
This document is from 1987. The same remains true today 30 years later–both for private industry and universities. Postdocs are still the oft-unsung heroes and heroines of research innovation and everyday scientific inquiry. But the ability to influence the scientific community through giving early-career researchers temporary jobs working for the tobacco industry also interested RJR by drawing talent that would then go on to work for other esteemed firms and universities.
The diffusion effect of getting researchers at the waist of the hourglass in their careers, would allow their postdoctoral research program to also bring recognition to RJR for their scientific endeavors, increasing their prestige.
Thus, for RJR, the manipulation of the postdoc is double: cheap high quality labor, and prestige by association, when the postdocs continue their careers as successful researchers, always marking on their resumes that they spent a postdoctoral research period at RJR’s research facilities.
Today, with co-authors Pamela M. Ling and Jesse Elias, our paper “The Pharmaceuticalization of the Tobacco Industry” appears in the Annals of Internal Medicine.
Our interview with Reuters is available here.
This work contributes to the study of industrial epidemics, and how corporations, instead of dying a quiet death as the world wakes up to the inutility of their products for life, metastasize into other structures to clean up the messes they continue to create–and to charge taxpayers for it (in this case, by getting government health care like the NHS in the UK, to pay for their so-called reduced-harm nicotine products).